Fennec Pharmaceuticals (TSX:FRX) Gross-Profit-to-Asset % : 157.20% (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Fennec Pharmaceuticals Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Fennec Pharmaceuticals's annualized Gross Profit for the quarter that ended in Dec. 2023 was C$48.56 Mil. Fennec Pharmaceuticals's average Total Assets over the quarter that ended in Dec. 2023 was C$30.89 Mil. Therefore, Fennec Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 157.20%.

Fennec Pharmaceuticals Gross-Profit-to-Asset % Historical Data

The historical data trend for Fennec Pharmaceuticals's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Gross-Profit-to-Asset % Chart

Fennec Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

0.74

6.03

73.85

Fennec Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															20.40	26.06	60.64	129.81	157.20

Competitive Comparison of Fennec Pharmaceuticals's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Fennec Pharmaceuticals's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fennec Pharmaceuticals's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Gross-Profit-to-Asset % falls into.

Fennec Pharmaceuticals Gross-Profit-to-Asset % Calculation

Fennec Pharmaceuticals's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	26.823	/	( (36.597	+	36.041)	/ 2 )
	=	26.823	/	36.319
	=	73.85 %

Fennec Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	48.564	/	( (25.747	+	36.041)	/ 2 )
	=	48.564	/	30.894
	=	157.20 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Fennec Pharmaceuticals Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Fennec Pharmaceuticals (TSX:FRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (TSX:FRX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

FENC:USA RV41:Germany

Address

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709

Website

https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.